AnaptysBio Inc [ANAB] stock is trading at $36.12, down -0.11%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The ANAB shares have gain 7.34% over the last week, with a monthly amount glided 17.96%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
AnaptysBio Inc [NASDAQ: ANAB] stock has seen the most recent analyst activity on October 13, 2025, when Barclays initiated its Overweight rating and assigned the stock a price target of $78. Previously, H.C. Wainwright upgraded its rating to Buy on June 04, 2025, and kept the price target unchanged to $38. On February 04, 2025, Wolfe Research initiated with a Outperform rating and assigned a price target of $25 on the stock. H.C. Wainwright downgraded its rating to a Neutral and decreased its price target to $19 on December 11, 2024. BTIG Research downgraded its rating to a Neutral. H.C. Wainwright started tracking with a Buy rating for this stock on July 22, 2024, and assigned it a price target of $55. In a note dated July 19, 2024, JP Morgan upgraded an Overweight rating on this stock and boosted its target price from $29 to $69.
AnaptysBio Inc [ANAB] stock has fluctuated between $12.21 and $37.00 over the past year. Currently, Wall Street analysts expect the stock to reach $68.2 within the next 12 months. AnaptysBio Inc [NASDAQ: ANAB] shares were valued at $36.12 at the most recent close of the market. An investor can expect a potential return of 88.82% based on the average ANAB price forecast.
Analyzing the ANAB fundamentals
AnaptysBio Inc [NASDAQ:ANAB] reported sales of 123.16M for the trailing twelve months, which represents a growth of 102.93%. Gross Profit Margin for this corporation currently stands at 0.99% with Operating Profit Margin at -0.7%, Pretax Profit Margin comes in at -1.08%, and Net Profit Margin reading is -1.08%. To continue investigating profitability, this company’s Return on Assets is posted at -0.4, Equity is -3.67 and Total Capital is -0.29. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -7.74.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 35.16 points at the first support level, and at 34.20 for the second support level. However, for the 1st resistance point, the stock is sitting at 37.73, and for the 2nd resistance point, it is at 39.34.
Ratios To Look Out For
For context, AnaptysBio Inc’s Current Ratio is 8.22. Also, the Quick Ratio is 8.22, while the Cash Ratio stands at 1.25. Considering the valuation of this stock, the price to sales ratio is 8.21.
Transactions by insiders
Recent insider trading involved LOUMEAU ERIC J, CHIEF LEGAL OFFICER, that happened on Sep 30 ’25 when 8240.0 shares were sold. Officer, ERIC J LOUMEAU completed a deal on Sep 30 ’25 to buy 8240.0 shares. Meanwhile, Director RENTON HOLLINGS sold 10231.0 shares on Aug 08 ’25.
